STOCK TITAN
  1. Home
  2. Sec-filings
  3. NEO
  4. [Form 4] NEOGENOMICS INC Insider Trading Activity

NeoGenomics (NEO) accounting chief sells 20,000 shares, keeps equity awards

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

NeoGenomics Inc. chief accounting officer Greg D. Aunan reported selling 20,000 shares of Common Stock on 2026-08-04 at $16.07 per share, leaving 5,153 shares held directly. He continues to hold multiple equity awards, including restricted stock units for 10,745 underlying shares and stock options for 28,662, 26,978, 31,163 and 36,825 underlying shares with exercise prices between $9.83 and $14.62.

Positive

  • None.

Negative

  • None.
Insider Aunan Greg D
Role Chief Accounting Officer
Sold 20,000 shs ($321K)
Type Security Shares Price Value
Sale Common Stock 20,000 $16.07 $321K
holding Restricted Stock Unit F1, F2 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F4 -- -- --
holding Stock Option (Right to Buy) F5 -- -- --
holding Restricted Stock Unit F6, F2 -- -- --
holding Stock Option (Right to Buy) F7 -- -- --
holding Restricted Stock Unit F8, F2 -- -- --
Holdings After Transaction: Common Stock — 5,153 shares (Direct); Restricted Stock Unit — 46,282 shares (Direct); Stock Option (Right to Buy) — 123,628 shares (Direct)
Footnotes (8)
  1. F1. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  2. F2. Once vested, the shares of common stock are not subject to expiration.
  3. F3. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  4. F4. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  5. F5. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  6. F6. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  7. F7. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  8. F8. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Shares sold 20,000 shares Common Stock sale on 2026-08-04 by Chief Accounting Officer
Sale price $16.07 per share Per-share price for 20,000-share Common Stock sale
Common shares held 5,153 shares Direct ownership after reported sale
RSUs outstanding 10,745 shares Restricted Stock Units granted May 2, 2024; underlying common shares
Stock options at $14.62 28,662 shares Options granted May 1, 2023; expire 2030-05-01
Stock options at $9.83 36,825 shares Options granted March 1, 2026; expire 2036-03-01
Restricted Stock Unit financial
"was granted 18,971 restricted stock units. The restricted stock units vest"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 28,662 underlying shares of Common Stock"
vest ratably financial
"The options vest ratably over the first three anniversary dates"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did NeoGenomics (NEO) officer Greg D. Aunan report in this Form 4?
Greg D. Aunan reported a sale of 20,000 NeoGenomics common shares on 2026-08-04 at $16.07 per share. After this transaction, he directly holds 5,153 common shares and retains several restricted stock unit and stock option awards over additional common stock.

How many NeoGenomics (NEO) shares does Greg D. Aunan hold after the reported sale?
After the 20,000-share sale, Greg D. Aunan directly holds 5,153 NeoGenomics common shares. In addition to this direct ownership, he has restricted stock units and stock options covering tens of thousands of additional underlying shares of NeoGenomics common stock.

At what price did Greg D. Aunan sell NeoGenomics (NEO) shares?
Greg D. Aunan sold 20,000 NeoGenomics common shares at $16.07 per share on 2026-08-04. This reported price represents the per-share amount for the transaction classified as a sale of common stock in the Form 4 filing.

What stock option awards in NeoGenomics (NEO) does Greg D. Aunan report holding?
Greg D. Aunan reports stock options over 28,662, 26,978, 31,163 and 36,825 shares of NeoGenomics common stock. These options have exercise prices of $14.62, $13.96, $11.86 and $9.83, with expiration dates ranging from 2030-05-01 to 2036-03-01.

What restricted stock unit (RSU) positions in NeoGenomics (NEO) are disclosed for Greg D. Aunan?
The filing shows restricted stock units over 10,745, 12,648 and 22,889 underlying NeoGenomics shares. Footnotes explain these RSUs were granted in 2024 and 2025 and vest ratably over the first three anniversary dates of each grant date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aunan Greg D
(Last)(First)(Middle)
9490 NEOGENOMICS WAY
(Street)
FORT MYERS FLORIDA 33912
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/04/2026S20,000D$16.075,153D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0 (1) (2)Common Stock10,74510,745D
Stock Option (Right to Buy)$14.62 (3)05/01/2030Common Stock28,66228,662D
Stock Option (Right to Buy)$13.96 (4)05/02/2034Common Stock26,97826,978D
Stock Option (Right to Buy)$11.86 (5)02/21/2035Common Stock31,16331,163D
Restricted Stock Unit$0 (6) (2)Common Stock12,64812,648D
Stock Option (Right to Buy)$9.83 (7)03/01/2036Common Stock36,82536,825D
Restricted Stock Unit$0 (8) (2)Common Stock22,88922,889D
Explanation of Responses:
1. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
2. Once vested, the shares of common stock are not subject to expiration.
3. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
4. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
5. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
6. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
7. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.
8. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Remarks:
/s/ Ali Olivo, Attorney-in-Fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR